Medical

Funding boost for breakthrough treatments and diagnostics research

Health Industry Hub | September 3, 2020 |
[Total: 1    Average: 5/5]

Medical News: The Australian Government is backing several Australian research projects (list below) aimed at finding breakthrough treatments, diagnostics and – the ultimate – a vaccine in the fight against COVID-19.

Our Government has allocated $10.4 million for 13 early stage biomedical projects through Biomedical Translation Bridge (BTB) program, which forms part of the landmark Medical Research Future Fund (MRFF).

Five of them are COVID-19 research projects receiving $4.1 million. A key project, conducted by the University of Melbourne, involves developing an innovative ventilated hood for patients in isolation.

Other COVID-19 research projects include a vaccine candidate being developed in South Australia, a new treatment for respiratory complications of COVID-19, a preventive nasal spray, and a rapid response test to predict how severely the disease will progress.

The remaining eight projects, receiving $6.3 million, will help patients of the future with new treatments and diagnostics for conditions such as muscular dystrophy, breast cancer, metabolic and fibrotic disease, prostate cancer, ataxia, antimicrobial resistance and the Zika virus.

Industry partners have contributed a further $28 million to the 13 projects, complementing our Government’s investment of $10.4 million – this means a total of $38.4 million is being invested into the biomedical sector. 

The BTB is a four year $22.3 million MRFF program, operated by MTPConnect.

The emphasis of the BTB program is on rapid translation of ideas into new products and treatments that will make a real difference to patients, both in Australia and globally.

BTB Round 2 Recipients

Bard1 Life Sciences Limited, VIC (ASX listed) is developing a novel high-throughput SubB2M-based liquid biopsy blood tests for breast cancer screening and monitoring based on a unique cancer-specific probe. 

Cincera Therapeutics Pty Ltd, VIC/SA is developing a new drug treatment for Metabolic and Fibrotic Disease.

Envision Sciences Pty Ltd, SA is developing diagnosis and prognostic detection methods for prostate cancer, using blood and tissue samples.

LBT Innovations Limited, SA (ASX listed) is developing APAS-AMR: An Automated Plate Assessment System for Anti-Microbial Resistance using Artificial Intelligence.

Pharmaxis Ltd, NSW (ASX listed) is developing compound PXS-4699 with tailored dual action to treat Duchenne Muscular Dystrophy.

The University of Adelaide, SA is developing a world-first needle-free Zika virus vaccine.

The Florey Institute of Neuroscience and Mental Health, VIC is developing a device for guiding therapy in ataxia and imbalance.

UniQuest Pty Ltd, QLDis developing first-in-class drug candidates for the treatment of prostate and other cancers.

BTB COVID-19 Round 3 Recipients

Dimerix Bioscience Pty Ltd, VIC (ASX listed) is developing a new treatment for respiratory complications as a result of COVID-19 in a global clinical study with a potential fast track pathway to clinical practice.

Starpharma Pty Ltd, VIC (ASX listed) is developing an intranasal spray, utilising an already-marketed, broad-spectrum antiviral dendrimer for COVID-19 and potential use in future pandemics.

SpeeDx Pty Ltd, NSW is developing the InSignia Respiratory Virus Host Response test – a rapid-response COVID-19 assay to enhance Australia’s current and future pandemic preparedness.

University of Melbourne, VIC is developing a novel ventilated hood for patient isolation to provide better patient respiratory treatment and protect hospital staff from COVID-19.

Vaxine Pty Ltd, SA is developing an Australian COVID-19 vaccine, COVAX-19, which comprises of a recombinant spike protein antigen formulated with Vaxine’s proprietary Advax™ adjuvant.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Marketing & Strategy

PRIME Award 2020 winners announced

Health Industry Hub | September 24, 2020 |

The first ever virtual PRIME Awards saw the best and brightest healthcare communications work recognised in the pharmaceutical and life […]

More


News & Trends - Pharmaceuticals

Pharma News - Australia’s first Antimicrobial Resistance Network to combat global health threat

Australia’s first Antimicrobial Resistance Network to combat global health threat

Health Industry Hub | September 24, 2020 |

Please log in to Health Industry Hub to view this content in the News menu → Pharmaceuticals sub-menu.

More


News & Trends - Medical Technology

MedTech News - Companies playing an important role in the robot-assisted surgery market

Companies playing an important role in the robot-assisted surgery market

Health Industry Hub | September 23, 2020 |

MedTech News: The market for surgical robots is expected to grow from USD 6.7 billion in 2020 to USD 11.8 […]

More


News & Trends - Pharmaceuticals

Pharma News - Roche acquires Inflazome co-founded by local researcher

Roche acquires Inflazome co-founded by local researcher

Health Industry Hub | September 23, 2020 |

Please log in to Health Industry Hub to view this content in the News menu → Pharmaceuticals sub-menu.

More